Post job

Explore jobs

Find specific jobs

Explore careers

Explore professions

Best companies

Explore companies

Impel NeuroPharma Leadership

Zippia score 3.9
OverviewSalaryRevenue

Reviews

CEO & Executives

Impel NeuroPharma executives

Here are further demographic highlights of the leadership team:
  • The Impel NeuroPharma executive team is 30% female and 70% male.
  • 57% of the management team is White.
  • 10% of Impel NeuroPharma management is Hispanic or Latino.
  • 15% of the management team is Black or African American.
Work at Impel NeuroPharma?
Share your experience

Rate Impel NeuroPharma's leaders' effectiveness in guiding the company.

Zippia waving zebra
Name & TitleBio
John D. Hoekman

Chief Scientific Officer

John D. Hoekman's LinkedIn

John Hoekman has focused on nasal drug delivery with an emphasis on delivery targeting the central nervous system using innovative device design and drug delivery systems. His research experience includes working with Dr. William Frey, one of the pioneers of nose-to-brain drug delivery, and Dr. Rodney Ho at the University of Washington. His unique background in both Physics and Pharmaceutics led to the development of Impel NeuroPharma’s core nasal delivery technology, the Pressurized Olfactory Delivery (POD) devices, of which he is co-inventor.

Michael Hite

Founder

Rodney Ho

Founder

Adrian Adams

Chairman

Timothy S. Nelson

Board Member

Ali J Satvat Mba

Board Member

Diane E Wilfong Cpa

Board Member

H Stewart Parker Mba

Board Member

Mahendra G Shah Ph.D.

Board Member

David D Allison Ph.D.

Board Member

Do you work at Impel NeuroPharma?

Does the leadership team provide a clear direction for Impel NeuroPharma?

Impel NeuroPharma jobs

Impel NeuroPharma founders

Name & TitleBio
John D. Hoekman

Chief Scientific Officer

John D. Hoekman's LinkedIn

John Hoekman has focused on nasal drug delivery with an emphasis on delivery targeting the central nervous system using innovative device design and drug delivery systems. His research experience includes working with Dr. William Frey, one of the pioneers of nose-to-brain drug delivery, and Dr. Rodney Ho at the University of Washington. His unique background in both Physics and Pharmaceutics led to the development of Impel NeuroPharma’s core nasal delivery technology, the Pressurized Olfactory Delivery (POD) devices, of which he is co-inventor.

Michael Hite

Founder

Rodney Ho

Founder

Impel NeuroPharma board members

Name & TitleBio
John D. Hoekman

Chief Scientific Officer

John D. Hoekman's LinkedIn

John Hoekman has focused on nasal drug delivery with an emphasis on delivery targeting the central nervous system using innovative device design and drug delivery systems. His research experience includes working with Dr. William Frey, one of the pioneers of nose-to-brain drug delivery, and Dr. Rodney Ho at the University of Washington. His unique background in both Physics and Pharmaceutics led to the development of Impel NeuroPharma’s core nasal delivery technology, the Pressurized Olfactory Delivery (POD) devices, of which he is co-inventor.

Adrian Adams

Chairman

Timothy S. Nelson

Board Member

Ali J Satvat Mba

Board Member

Diane E Wilfong Cpa

Board Member

H Stewart Parker Mba

Board Member

Mahendra G Shah Ph.D.

Board Member

David D Allison Ph.D.

Board Member

Aaron Royston

Board Member

Jon Congleton

Board Member

Impel NeuroPharma executives FAQs

Impel NeuroPharma highest paying jobs

Updated November 18, 2022

Zippia gives an in-depth look into the details of Impel NeuroPharma, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Impel NeuroPharma. The employee data is based on information from people who have self-reported their past or current employments at Impel NeuroPharma. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Impel NeuroPharma. The data presented on this page does not represent the view of Impel NeuroPharma and its employees or that of Zippia.

Impel NeuroPharma may also be known as or be related to IMPEL NEUROPHARMA INC, Impel NeuroPharma, Impel NeuroPharma, Inc., Impel Neuropharma, Impel Neuropharma, Inc. and Impel Pharmaceuticals Inc.